Posted by Michael Wonder on 27 Feb 2026
Xspray Pharma resubmits its FDA application for Dasynoc
26 February 2026 - Xspray Pharma has resubmitted its application for market approval for Dasynoc to the US FDA.
Dasynoc is the company's lead product candidate – an amorphous dasatinib for the treatment of leukaemia.
